Cristin Hubbard, BioMarin Pharmaceutical
BioMarin Pharmaceutical, a US company developing biopharmaceuticals for rare diseases driven by genetic causes has named Cristin Hubbard as executive VP and Chief Commercial Officer. Hubbard will assume responsibility for the company’s global commercial operations from 20 May.
Julio Triana, Bayer
The Supervisory Board of German pharma and biotech Bayer has appointed Julio Triana to its Board of Management. He will also become President of the Consumer Health Division from 1 May 2024, succeeding Heiko Schipper, who is leaving the company.
Jon Kemp, DuPont Electronics & Industrial
Jon Kemp, President, DuPont Electronics & Industrial, has been named Chair of the Board of Industry Leaders of SEMI, a global industry association serving the electronics design and manufacturing supply chain. SEMI connects over 3000 member companies and 1.5m professionals worldwide.
Jeannie Lee, GSK
UK biopharma GSK has announced that Jeannie Lee has been appointed as a non-executive Director. Lee is the Phillip Sharp Endowed Chair in Molecular Biology and Acting Chair of the Department of Molecular Biology at the Massachusetts General Hospital. She is also Professor of Genetics (and Pathology) at Harvard Medical School and specialises in RNA biology.
Peter Soelkner, Oxford Biomedica
Oxford Biomedica, a UK cell and gene therapy CDMO, has announced that CDMO expert Peter Soelkner will join its Board as a Non-Executive Director. Also, Michael Hayden has informed the Board that he does not intend to stand for re-election at the upcoming June AGM but will continue to be an adviser to the Science and Technology Advisory Committee.
John Mendlein, Vesalius Therapeutics
Vesalius Therapeutics, a US biotechnology company developing drugs for common diseases, has announced that John Mendlein will become the company’s Executive Chairman and interim CEO. He succeeds Chris Austin, who joined the company in 2021 and who is taking a new role as Senior VP, Research Technologies at UK biopharma GSK.
Ramiro Ribeiro, EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, a US company developing and commercialising therapeutics to improve the lives of patients with serious retinal diseases, has named Ramiro Ribeiro as its next CMO. Ribeiro succeeds Dario Paggiarino who has served as EyePoint’s CMO since 2016. Ribeiro joins EyePoint from Apellis Pharmaceuticals.
Max Preisenberger, Evonik
German specialty chemicals company Evonik has appointed Max Preisenberger as the new head of its catalysts business line. Preisenberger, who was previously responsible for Finance and Strategy in the Specialty Additives division, takes over from Sanjeev Taneja, who has retired.
Ben Stephens, Sitryx Therapeutics
UK biopharma Sitryx Therapeutics, which works on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, has announced two appointments: Ben Stephens as COO and Gordon Dingwall as Head of Clinical Operations.
John Kuijpers, Moligo Technologies
Moligo Technologies, a Swedish biotech developing safer and more accessible gene-based technologies and therapies with enzymatically produced, single-stranded, ultra-pure, industrial scale DNA, has appointed John Kuijpers as its new Chief Business Officer.
Véronique Foutel, InBrain Pharma
InBrain Pharma, a French biotech specialising in brain infusion of drugs for neurological disorder management, has announced the appointment of Véronique Foutel as the company’s next CEO. Matthieu Fisichella, InBrain co-founder, and current CEO since 2018, will remain with the company and becomes CSO.
AkzoNobel, Supervisory Board appointments
Dutch paints and performance coatings company AkzoNobel has announced that Jaska de Bakker, Ute Wolf and Wouter Kolk will be nominated for appointment to the Supervisory Board, while Byron Grote – currently Supervisory Board Deputy Chair and Chair of the Audit Committee – will be nominated for a fourth one year term. The appointments and re-appointment will be put to shareholders for approval at the AGM on 25 April.
David Miller, Genesis Research Group
Genesis Research Group, a US consultancy that provides real-world evidence, health economics and outcomes research, and market access services, has appointed David Miller as Chairman and CEO. Prior to Genesis Research Group, Miller was Senior VP of Global Market Access at Biogen with responsibility for securing patient access to Biogen products worldwide.
Holly Peng, International Association of Horticultural Producers
During the International Association of Horticultural Producers (AIPH) Spring Meeting in Doha, Qatar, Members of the General Meeting elected Holly Peng from China as its new Vice President. Peng is the Deputy Secretary General of the China Flower Association and an expert in the horticultural and landscaping sector, committed to finding sustainable solutions for urban greening.
Mathieu Charvériat, Theranexus
Theranexus, a French biopharma operating in the treatment of rare neurological diseases, has named Mathieu Charvériat as Chairman of its Board of Directors following the resignation of Franck Mouthon. Under the new setup, Mouthon will continue to serve as a non-executive director in tandem with his new responsibilities as CEO of the Agency for health research programmes. Charvériat will continue as CEO in addition to chairing the Board of Directors.
Advisory Board appointments, 4BIO Capital
4BIO Capital, a UK-based firm investing in venture capital and public equities in life sciences, has appointed biopharma veteran Abbas Hussain and vectorology expert Leszek Lisowski to its Advisory Board.
Adrian Schreyer, Anagenex
Anagenex, a US pre-clinical drug-discovery biotech that pairs large-scale data generation with proprietary AI to discover the next generation of small-molecule medicines, has named Adrian Schreyer as its next CTO.
Joseph Bertelsen, Nuclera
UK biotech Nuclera, which works in rapid protein expression and purification screening through its benchtop protein platform, has named Joseph Bertelsen as CCO.
Metrohm USA, Young Chemist Award to Katelyn Michael of University of Wisconsin-Madison
Metrohm USA, the US subsidiary of Swiss manufacturer of precision instruments for chemical analysis Metrohm AG, has announced the winner of this year’s $10,000 Young Chemist Award. Katelyn Michael of the University of Wisconsin-Madison was recognised for her research on the sustainable degradation of perfluorooctanesulfonic acid, a persistent pollutant in the environment.
Visit Blog
.ashx?h=300&w=290&hash=565BE14D10ECA322C8688A4BD28A1C2C)